About relationship between chronic obstructive pulmonary disease and anemia
https://doi.org/10.18093/0869-0189-2018-28-6-730-735
Abstract
Until recently, compensatory erythrocytosis related to impaired renal blood circulation, treatment with some pharmacological agent, smoking, etc., was considered as one of the obligatory signs of advanced chronic obstructive pulmonary disease (COPD). Currently, normochromic normocytic anemia in COPD patients was diagnosed according to results of several studies. Prevalence data on anemia in COPD differ significantly from 7.5% to 33%. It is unclear, if anemia is a systemic feature of COPD or comorbidity. This article is a review about relationship between COPD and anemia. Most authors consider anemia in COPD as a condition associated with chronic disease, but mechanisms of its development are not fully investigated. There are few studies of effective treatment of anemia in COPD and their results are controversial. New experimental and clinical studies on mechanisms of anemia in COPD are required to improve management of such patients, their quality of life and outcomes.
About the Authors
Yu. G. Zhusina
N.N.Burdenko Voronezh State Medical University, Healthcare Ministry of Russia
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
Yuliya G. Zhusina - Postgraduate Student, Department of General Internal Medicine.
Ul. Studencheskaya 10, Voronezh, 394622, tel.: (920) 443-07-88
Competing Interests: No conflict of interest
A. V. Budnevskiy
N.N.Burdenko Voronezh State Medical University, Healthcare Ministry of Russia
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
Andrey V. Budnevskiy - Doctor of Medicine, Professor, Vice-rector for Academic Affairs, Head of Department of General Internal Medicine.
Ul. Studencheskaya 10, Voronezh, 394622, tel.: (4732) 63-81-30
Competing Interests: No conflict of interest
A. A. Fes’kova
N.N.Burdenko Voronezh State Medical University, Healthcare Ministry of Russia
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
Anna A. Fes’kova - Candidate of Medicine, Assistant Lecturer, Department of General Internal Medicine.
Ul. Studencheskaya 10, Voronezh, 394622, tel.: (920) 440-02-27
Competing Interests: No conflict of interest
E. S. Ovsyannikov
N.N.Burdenko Voronezh State Medical University, Healthcare Ministry of Russia
Russian Federation
Competing Interests: No conflict of interest
Russian Federation
Evgeniy S. Ovsyannikov, Candidate of Medicine, Associate Professor, Department of General Internal Medicine.
Ul. Studencheskaya 10, Voronezh, 394622, tel.: (910) 340-52-81
Competing Interests: No conflict of interest
References
1. Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet. 2012; 380 (9859): 2095–2128. DOI: 10.1016/S0140-6736(12)61728-0.
2. Starodubov V.I., Leonov S.A., Vaysman D.Sh. An analysis of general trends in change of morbidity of chronic obstructive lung diseases and bronchiectasis in Russian Federation, 2005 – 2012. Meditsina. 2013; (4): 1–31 (in Russian).
3. Kokosov A.N. Chronic bronchitis and obstructive lung disease. In: Kokosov A.N., ed. An Evolution of Knowledge on Chronic Bronchial Lesions and Classification of the Diseases. Saint-Petersburg: Lan’; 2002: 11–19 (in Russian).
4. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33 (5): 1165–1185. DOI: 10.1183/09031936.00128008.
5. Prozorova G. G., Budnevskiy A. V., Ovsyannikov E. S. et al. About systemic features of chronic obstructive pulmonary disease. Molodoy uchenyy. 2015; 13 (93): 308–310. (in Russian).
6. Chuchalin A.G. Chronic Obstructive Lung Diseases. Moscow: Atmosfera; 2008 (in Russian).
7. Vanfleteren L.E., Spruit M.A., Groenen M. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 187 (7): 728–735. DOI: 10.1164/rccm.201209-1665OC.
8. Nonikov V.E. Chronic obstructive pulmonary disease (COPD): diagnosis and treatment. Pul’monologiya. 2004; 6 (5): 12–17 (in Russian).
9. Ovcharenko S.I., Kapustina V.A. Recent advances in therapy of chronic obstructive pulmonary disease (results of UPLIFT study). Farmateka. 2009; 5 (179): 33–38 (in Russian).
10. Anía B.J., Suman V.J., Fairbanks V.F. et al. Incidence of anemia in older people: an epidemiologic study in a well defined population. J. Am. Geriatr. Soc. 1997; 45 (7): 825–831. DOI: 10.1111/j.1532-5415.1997.tb01509.x.
11. Chambellan A., Chailleux E., Similowski T. Prognostic value of hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2005; 128 (3): 1201–1208. DOI: 10.1378/chest.128.3.1201.
12. Dvoretsky L.I. Anemia in patients with chronic obstructive pulmonary disease: is it co-morbidity or a systemic manifestation? Pul'monologiya. 2012; (2): 5–11. DOI: 10.18093/0869-0189-2012-0-2-5-11 (in Russian).
13. Guidi G.C., Lechi Santonastaso C. Advancements in anemias related to chronic conditions. Clin. Chem. Lab. Med. 2010; 48 (9): 1217–1226. DOI: 10.1515/CCLM.2010.264.
14. Budnevskiy A.V., Esaulenko I.E., Ovsyannikov E.S., Zhusina Yu.G. Anemia in chronic obstructive pulmonary disease. Terapevticheskiy arkhiv. 2016; 88 (3): 96–99. DOI: 10.17116/terarkh201688396-99 (in Russian).
15. Nissenson A.R., Goodnough L.T., Dubois R.W. Anemia: not just an innocent bystander? Arch. Intern. Med. 2003; 163 (12): 1400–1404. DOI: 10.1001/archinte.163.12.1400.
16. John M., Hoernig S., Doehner W. et al. Anemia and inflammation in COPD. Chest. 2005; 127 (3): 825–829. DOI: 10.1378/chest.127.3.825.
17. Halpern M.T., Zilberberg M.D., Schmier J.K. et al. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Eff. Resour. Alloc. 2006; (4): 17. DOI: 10.1186/1478-7547-4-17.
18. Shorr A.F., Doyle J., Stern L. et al. Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications. Curr. Med. Res. Opin. 2008; 24 (4): 1123–1130. DOI: 10.1185/030079908X280699.
19. Fidan A., Tokmak M., Kiral N. et al. Anemia in COPD and related factors. Chest. 2010; 138 (4, Suppl.): 457A. DOI: 10.1378/chest.10779.
20. Parveen S., Rangreze I., Ahmad S. N. et al. Prevalence of anemia in patients with COPD and its potential impact on morbidity of COPD patients. Int. J. Clin. Med. 2014; 5 (8): 452–458. DOI: 10.4236/ijcm.2014.58063.
21. Budnevskiy A.V., Voronina E.V., Ovsyannikov E.S. et al. Chronic anemia as a sign of chronic obstructive pulmonary disease. Klinicheskaya meditsina. 2017; 95 (3): 201–206 (in Russian).
22. Wouters E. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2 (1): 26–33. DOI: 10.1513/pats.200408-039MS.
23. Weiss G., Goodnough L.T. Anemia of chronic disease. N. Engl. J. Med. 2005; 352 (10): 1011–1023. DOI: 10.1056/NEJMra041809.
24. Pavlov A.D., Morshchakova E.F., Rumyantsev A.G. Erythropoiesis, Erythropoietin, and Iron. Moscow: GEOTAR-media; 2011 (in Russian).
25. Schiffman F.J. Hematologic Pathophysiology. (Translated from English). Moscow: Binom; Saint-Petersburg: Nevskiy dialect; 2000 (in Russian).
26. Kullich W., Niksic F., Burmucic K. et al. [Effects of the chemokine MIP-1alpha on anemia and inflammation in rheumatoid arthritis]. Z. Rheumatol. 2002; 61 (5): 568–576. DOI: 10.1007/s00393-002-0410-x (in German).
27. Zhu Y., Ye D., Huang Z. [The correlation of cytokines TNF alpha, IFN-gamma, Epo with anemia in rheumatoid arthritis]. Zhonghua Xue Ye Xue Za Zhi. 2000; 21 (11): 587–590 (in Chinese).
28. Hunt J.R., Roughead Z.K. Adaptation of iron absorption in men consuming diets with high or low iron bioavailability. Am. J. Clin. Nutr. 2000; 71 (1): 94–102. DOI: 10.1093/ajcn/71.1.94.
29. Eisenstein R.S., Bieming K.P. Iron regulatory proteins, iron responsive elements and iron homeostasis. J. Nutr. 1996; 128 (12): 2295–2298. DOI: 10.1093/jn/128.12.2295.
30. Park S., Jung C. W., Kim K. et al. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. 2015; 6 (40): 42803–42812. DOI: 10.18632/oncotarget.5658.
31. Punnonen K., Irjala K., Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997; 89 (3): 1052–1057.
32. Nemeth E., Ganz T. Anemia of inflammation. Hematol. Oncol. Clin. North. Am. 2014; 28 (4): 671–681. DOI: 10.1016/j.hoc.2014.04.005.
33. Casaburi R., Bhasin S., Cosentino L. et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 870–878. DOI: 10.1164/rccm.200305-617OC.
34. Tsantes A.E., Tassiopoulos S.T., Papadhimitriou S.I. et al. Theophylline treatment may adversely affect the anoxia- induced erythropoietic response without suppressing erythropoietin production. Eur. J. Clin. Pharmacol. 2003; 59 (5–6): 379–383. DOI: 10.1007/s00228-003-0640-0.
35. Marathias K.P., Agroyannis B., Mavromoustakos T. et al. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr. Top. Med. Chem. 2004; 4 (4): 483–486. DOI: 10.2174/1568026043451311.
36. Cote C., Zilberberg M.D., Mody S.H. et al. Haemoglobin level and its clinical impact in a cohort of patients with CODP. Eur. Respir. J. 2007; 29 (5): 923–929. DOI: 10.1183/09031936.00137106.
37. Agusti A.G., Noguera A, Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (2): 347–360. DOI: 10.1183/09031936.03.00405703.
38. MacCallum P.K. Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smoker. Proc. Am. Thorac. Soc. 2005. 2 (1): 34–43. DOI: 10.1513/pats.200406-036MS.
39. Kautz L., Jung G., Valore E.V. et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 2014; 46 (7): 678–684. DOI: 10.1038/ng.2996.
40. Tarantino G., Brilli E., Giordano G., Torelli A. Innovative oral iron supplement (sucrosomial iron) is able to downregulate hepsidin release during inflammation: in vitro study. Blood. 2015; 126 (23): 4563.
41. Theurl I., Schroll A., Sonnweber T. et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood. 2011; 118 (18): 4977–4984. DOI: 10.1182/blood-2011-03-345066.
42. Querbes W., Bogorad R.L., Moslehi J. et al. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood. 2012; 120 (9): 1916–1922. DOI: 10.1182/blood-2012-04-423715.
43. Schonhofer B., Wenze I.M., Geibe I.M., Kohler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit. Care Med. 1998; 26 (11): 1824–1828. DOI: 10.1097/00003246-199811000-00022.
44. Budnevskiy A.V., Tsvetikova L.N., Voronina E.V. et al. Erythroferrone as an erythroid regulator of iron exchange. Gematologiya i transfuziologiya. 2016; 61 (3): 161–163 (in Russian).
45. Budnevskiy A.V., Provotorov V.M., Ul’yanova M.I. Chronic obstructive pulmonary disease and anemia: clinical signs and therapeutic strategy. Klinicheskaya meditsina. 2016; 94 (9): 677–683 (in Russian).
46. Fedorova T.A., Ekkert N.V., Chernekhovskaya N.E. et al. Effects of antiinflammatory therapy in patients with chronic obstructive pulmonary disease. Klinicheskaya meditsina. 2005; 85 (7): 24–29 (in Russian).
Review
For citations:
Zhusina Yu.G., Budnevskiy A.V., Fes’kova A.A., Ovsyannikov E.S. About relationship between chronic obstructive pulmonary disease and anemia. PULMONOLOGIYA. 2018;28(6):730-735. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-6-730-735
Views:
2014
Email this article 